查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1807979

神經調節設備市場按設備類型、控制機制、技術、年齡層、治療領域、最終用戶和分銷管道分類 - 全球預測 2025-2030

Neuromodulation Devices Market by Device Type, Control Mechanism, Technology, Age Group, Therapeutic Area, End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

神經調節設備市場預計在 2024 年價值 50.8 億美元，在 2025 年成長至 54.5 億美元，到 2030 年達到 78 億美元，複合年成長率為 7.40%。

主要市場統計數據
基準年2024年 50.8億美元
預計2025年 54.5億美元
預測年份 2030 78億美元
複合年成長率（%） 7.40%

展望神經調節設備的未來，重點在於新臨床應用中的機會與挑戰

神經調節裝置透過向特定神經通路提供定向電刺激或磁刺激，徹底改變了複雜神經、精神和疼痛相關疾病的治療。隨著臨床應用從帕金森氏症和慢性疼痛等既定適應症擴展到重度憂鬱症和癲癇等新領域，相關人員必須適應快速的技術創新、不斷變化的監管要求和日益激烈的競爭環境。本簡介概述了當前產業格局的關鍵動態，並為深入分析提供了基礎觀點。

透過突破性創新和不斷變化的患者需求，揭示神經調節設備產業的變革

在材料科學、數據分析和法規適應性突破的推動下，神經調節設備領域正在經歷一場變革。生物相容性電極塗層和節能電池系統的最新進展，使得更小、更耐用、能夠提供精確調節刺激的植入式設備得以開發。同時，由機器學習演算法驅動的軟體創新正在簡化個人化治療通訊協定，提高回應率並減少不利事件。

分析2025年美國新關稅對供應鏈動態和相關人員策略的累積影響

隨著2025年美國新關稅的實施，全球神經調節供應鏈將迎來重大曲折點。包括微電極和特種聚合物在內的精密零件的進口關稅正在增加設備製造商的製造成本。為此，各公司正在調整籌資策略，並與國內供應商建立更緊密的夥伴關係關係，以減輕這些額外關稅的影響。

關鍵細分洞察揭示了多樣化的患者群體，技術和最終用戶偏好推動著市場的發展

深層腦部刺激器和脊髓刺激設備等侵入式平台與經顱直流電刺激和經顱磁刺激等非侵入式治療方式並存。在侵入式治療領域，薦骨神經刺激器和迷走神經刺激設備為泌尿系統和消化系統疾病開闢了重要的治療途徑，而深部腦部刺激仍是運動障礙的黃金標準。另一方面，非侵入式技術正在透過提供風險更低、更便捷的門診治療程序，擴大其在精神疾病領域的應用。

了解美洲、歐洲、中東和非洲以及亞太地區的區域特徵和戰略成長機會

美洲生態系統以成熟的支付環境和先進的外科手術基礎設施為特色。領先的學術醫療中心與設備製造商之間的前沿合作正在加速先進植入式系統的普及。同時，北美的報銷政策非常嚴格，一旦獲得可靠的臨床證據，即可提供清晰的市場准入途徑。因此，各公司正專注於縱向療效研究，以滿足不同相關人員的需求。

領先的神經調節設備製造商的策略和競爭定位將決定該行業的未來發展軌跡

領先的製造商正在採用獨特的策略來鞏固其在神經調節領域的地位。Medtronic正利用其在植入式技術領域的深厚專業知識和全球製造地，擴展其針對運動障礙的閉合迴路產品組合。與學術中心的合作提供了重要的長期安全性和有效性數據，增強了付款人的信心。波士頓科學以其在心臟和周邊介入領域強大的產品組合而聞名，目前正在向脊髓刺激設備和薦骨神經刺激器領域拓展業務，並專注於支援遠端監控的整合數位平台。

為行業領導者提供切實可行的建議，以應對監管複雜性和應用障礙，並加速神經調節領域的創新

產業領導者應優先開發封閉回路型神經調節系統，利用即時數據分析最佳化治療效果。投資可互通的軟體架構，可以無縫整合到現有的醫院資訊系統和遠端患者監護平台，從而提高臨床醫生的接受度，並增強支付方的證據產生能力。

嚴謹的調查方法細節，包括初步訪談、二次資料分析和三角測量，以獲得可靠的市場洞察力

為確保研究結果的有效性和可靠性，本研究採用了全面的調查方法，包括一手資料研究和二手資料研究。二手資料研究包括深入檢索公開的監管文件、同行評審期刊報導、臨床試驗註冊中心和專利資料庫。對這些資訊來源進行了系統分析，以確定關鍵地區的新興技術趨勢、資金籌措模式和不斷變化的報銷框架。

關於新興神經調節設備技術利益相關相關人員的策略重要性和未來方向的考慮總結

摘要，神經調節設備產業正處於一個關鍵的十字路口，其特點是快速的技術創新、不斷變化的監管模式以及相關人員不斷變化的期望。閉合迴路和非侵入式治療模式正在融合，以提高治療精準度，而新的價格結構和供應鏈重組正在重塑商業策略。能夠有效整合高階分析技術、促進策略合作並維持供應鏈韌性的公司將成為產業領跑者。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 用於個人化神經治療的封閉回路型深部腦部刺激系統的開發
  • 將非侵入性經顱磁刺激器與穿戴式健康監測器結合
  • 植入式迷走神經刺激設備在治療難治性癲癇和憂鬱症的進展
  • 一種用於精確無線神經迴路控制的新型光遺傳神經調節方法
  • 監管核准流程簡化了全球新型神經調節設備的臨床試驗
  • 採用人工智慧演算法即時最佳化刺激參數，以改善患者治療效果
  • 增加對微型神經調節系統的投資，實現患者居家護理

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第 8 章神經調節設備市場（依設備類型）

  • 侵入性設備
    • 深層腦部刺激器
    • 薦骨神經刺激器
    • 脊髓刺激設備
    • 迷走神經刺激設備
  • 非侵入式設備
    • 經顱直流電刺激
    • 經顱磁刺激

9. 神經調節設備市場（依控制機制）

  • 閉合迴路
  • 開放回路

第 10 章 神經調節設備市場（依技術）

  • 電刺激
  • 磁刺激
  • 光遺傳學刺激
  • 超音波刺激

第 11 章神經調節設備市場（依年齡層）

  • 成人
  • 老年人
  • 孩子們

第 12 章神經調節設備市場（按治療領域）

  • 消化系統和泌尿系統疾病
  • 神經系統疾病
    • 肌張力不全症
    • 癲癇
    • 帕金森氏症
  • 疼痛管理
    • 慢性疼痛
    • 神經病變疼痛
  • 精神疾病
    • 憂鬱症
    • 強迫症

第 13 章神經調節設備市場（依最終用戶）

  • 門診手術中心
  • 診所
  • 醫院
  • 研究所

第 14 章神經調節設備市場（依通路）

  • 離線
  • 線上

第 15 章美洲神經調節設備市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

第 16 章歐洲、中東和非洲的神經調節設備市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

第 17 章：亞太神經調節設備市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第18章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Abbott Laboratories
    • Aleva Neurotherapeutics SA
    • Biotronik SE & Co. KG
    • Boston Scientific Corporation
    • BrainsWay Ltd.
    • ElectroCore, Inc.
    • Integer Holdings Corporation
    • Laborie
    • Life Science Outsourcing, Inc.
    • LivaNova PLC
    • Medtronic plc
    • Neuromod Devices Limited
    • Neuronetics, Inc.
    • Neuropace Inc.
    • NeuroSigma, Inc.
    • Nexstim Oyj
    • Saluda Medical Pty Ltd
    • Soterix Medical Inc.
    • Synapse Biomedical Inc.
    • Synergia Medical SA
    • tVNS Technologies GmbH

第19章 研究人工智慧

第20章 研究統計

第21章 研究聯絡人

第22章 研究報導

第23章 附錄

Product Code: MRR-205091A88963

The Neuromodulation Devices Market was valued at USD 5.08 billion in 2024 and is projected to grow to USD 5.45 billion in 2025, with a CAGR of 7.40%, reaching USD 7.80 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 5.08 billion
Estimated Year [2025] USD 5.45 billion
Forecast Year [2030] USD 7.80 billion
CAGR (%) 7.40%

Setting the Stage for the Future of Neuromodulation Devices by Highlighting Opportunities and Challenges in Emerging Clinical Applications

Neuromodulation devices are revolutionizing the treatment of complex neurological, psychiatric, and pain-related disorders by delivering targeted electrical or magnetic stimuli to specific neural pathways. As clinical applications expand from established indications such as Parkinson's disease and chronic pain into emerging areas like major depressive disorder and epilepsy, stakeholders must adapt to an environment defined by rapid innovation, evolving regulatory requirements, and escalating competition. This introduction outlines the crucial dynamics that underpin the current industry landscape, offering a foundational perspective for deeper analysis.

Firstly, the convergence of advanced hardware miniaturization and sophisticated algorithmic control mechanisms has driven the development of next-generation systems that prioritize safety, efficacy, and patient comfort. As closed loop feedback becomes more prevalent, the ability to monitor and adjust stimulation parameters in real time is setting new standards for therapeutic outcomes. Meanwhile, strategic investments in optogenetic and ultrasonic stimulation technologies are broadening the scope of neuromodulation, offering the potential to treat conditions previously deemed intractable.

Furthermore, the intersection of reimbursements, health economics, and stakeholder collaboration is redefining commercialization strategies. Payers and providers are increasingly demanding robust clinical evidence that demonstrates long-term cost-effectiveness. Consequently, successful market entrants will be those who not only innovate at the technical level but also build integrated value propositions aligned with evolving healthcare ecosystems.

Unraveling the Transformative Shifts Reshaping the Neuromodulation Device Industry through Breakthrough Innovations and Evolving Patient Needs

The neuromodulation device landscape is experiencing transformative shifts driven by breakthroughs in materials science, data analytics, and regulatory adaptation. Recent advances in biocompatible electrode coatings and energy-efficient battery systems have enabled the creation of implantable devices that are smaller, more durable, and capable of delivering precisely calibrated stimulation. At the same time, software innovations powered by machine learning algorithms are streamlining the personalization of therapy protocols, thereby improving response rates and reducing adverse events.

In parallel, the emergence of noninvasive technologies such as transcranial magnetic stimulation and transcranial direct current stimulation is redefining the treatment paradigm by offering outpatient solutions with minimal side effects. These modalities are gaining traction not only in major metropolitan healthcare centers but also in community clinics, where ease of use and patient comfort drive adoption. Regulatory bodies have responded by establishing more flexible frameworks that expedite clinical approvals while maintaining rigorous safety and performance standards.

Additionally, the growing trend toward decentralized clinical trials and real-world evidence collection is reshaping stakeholder expectations around data transparency and long-term outcome measurement. This shift underscores the need for robust post-market surveillance programs and interdisciplinary research collaborations. As a result, manufacturers and clinicians are coalescing around new models of evidence generation that leverage digital health platforms and patient-reported outcome measures to validate therapeutic value continuously.

Analyzing the Cumulative Impact of Newly Implemented United States Tariffs in 2025 on Supply Chain Dynamics and Stakeholder Strategies

The implementation of new United States tariffs in 2025 has introduced a significant inflection point in the global neuromodulation supply chain. Import duties on precision components, including microelectrodes and specialized polymers, have elevated production costs for device manufacturers. In response, companies are reevaluating their sourcing strategies and forging closer partnerships with domestic suppliers to mitigate the impact of these additional levies.

Moreover, the cumulative effect of tariff-related cost pressures is prompting organizations to revisit their pricing models and reimbursement negotiations. As device costs increase, healthcare providers and payers are demanding more comprehensive clinical data to justify higher reimbursement rates. Consequently, companies are accelerating investments in real-world evidence studies that demonstrate long-term cost savings and enhanced patient outcomes.

To address these challenges proactively, several leaders have reshaped their manufacturing footprints, relocating certain production lines to low-cost regions while retaining critical assembly and quality control processes domestically. This hybrid approach balances tariff avoidance with stringent compliance to U.S. regulatory standards. As a result, industry players are pioneering new operational frameworks that blend global efficiency with regional agility, thereby reinforcing supply chain resilience and sustaining market momentum.

Revealing Key Segmentation Insights to Illuminate Diverse Patient Populations Technologies and End User Preferences Driving Market Evolution

Diverse device typologies underpin the neuromodulation market's complexity, with invasive platforms such as deep brain stimulators and spinal cord stimulators coexisting alongside emerging noninvasive modalities including transcranial direct current stimulation and transcranial magnetic stimulation. Within the invasive category, sacral nerve stimulators and vagus nerve stimulators have unlocked critical treatment pathways for urinary and gastrointestinal disorders, whereas deep brain stimulation remains the gold standard for movement disorders. Conversely, noninvasive technologies are extending applications into psychiatric conditions, offering a lower-risk profile and simplified outpatient procedures.

Control mechanisms further differentiate competitive offerings, as closed loop systems integrate continuous neural feedback to adapt stimulation parameters dynamically, enhancing safety and efficacy. Open loop configurations, while established and cost-effective, are now complemented by these next-generation designs that promise higher therapeutic precision. As such, market participants are prioritizing investments in sensor integration and advanced analytics to support automated adjustments based on real-time patient data.

Underlying these mechanical distinctions, a spectrum of stimulation modalities-from electrical and magnetic to optogenetic and ultrasonic-provides a rich array of therapeutic options. Electrical stimulation remains the backbone of most implantable solutions, yet magnetic and ultrasonic techniques are gaining traction due to their noninvasive delivery and potential for finer spatial targeting. Concurrently, optogenetic approaches, still largely in experimental stages, herald a future where genetic modulation can be precisely controlled.

Age group considerations also play a vital role in technology adoption and clinical trial design. While adult and geriatric populations have historically been the primary focus, pediatric use cases are emerging in epilepsy management and certain movement disorders. These developments necessitate device miniaturization and tailored safety protocols to accommodate younger patients.

Disorders spanning neurological, psychiatric, pain management, and gastrointestinal or urological domains illustrate the breadth of therapeutic areas. Neurological conditions such as dystonia, epilepsy, and Parkinson's disease represent core applications, while chronic and neuropathic pain management regimes drive spinal cord stimulator utilization. Psychiatric indications including depression and obsessive-compulsive disorder are increasingly served by both invasive and noninvasive systems, reflecting interdisciplinary collaboration between neurology and psychiatry.

Lastly, end user channels vary from ambulatory surgical centers and high-acuity hospitals to specialized research institutes and outpatient clinics. Distribution pathways blend traditional offline channels with burgeoning online platforms that facilitate telehealth-enabled device monitoring and remote programming. This multi-faceted segmentation underscores the importance of customized strategies that align product features with clinical settings and patient preferences.

Deciphering Regional Nuances and Strategic Growth Opportunities across the Americas Europe Middle East Africa and Asia Pacific Territories

Within the Americas, the ecosystem is characterized by a mature payer environment and high levels of surgical infrastructure. Cutting-edge research collaborations between leading academic medical centers and device manufacturers have accelerated the adoption of advanced implantable systems. Meanwhile, reimbursement policies in North America, though stringent, provide a clear pathway for market entry once robust clinical evidence is secured. Consequently, companies are focusing on longitudinal outcome studies to satisfy diverse stakeholder requirements.

In Europe, the Middle East, and Africa region, heterogenous regulatory frameworks coexist alongside emerging initiatives to harmonize market access protocols. Western Europe continues to adopt noninvasive neuromodulation modalities at a favorable pace, driven by shared-value health economics models. At the same time, Gulf Cooperation Council countries demonstrate strong interest in advanced therapies, incentivizing pilot programs that showcase real-world benefits. Emerging markets in Africa remain nascent but present long-term growth potential as infrastructure investments and healthcare investments climb.

Asia-Pacific exhibits dynamic expansion fueled by government-led healthcare modernization and growing demand for minimally invasive treatments. Japan and Australia spearhead clinical acceptance of both invasive and noninvasive platforms, supported by local manufacturing incentives. In China and India, rapid urbanization and rising healthcare expenditure are catalyzing pilot reimbursement programs, challenging international companies to navigate country-specific regulations and distribution complexities effectively. As such, the region demands agile market entry strategies tailored to each jurisdiction's unique nuances.

Exploring Strategies and Competitive Positioning of Leading Neuromodulation Device Manufacturers Shaping the Industry's Future Trajectory

Leading manufacturers have adopted distinct strategies to fortify their positions within the neuromodulation domain. Medtronic has leveraged its deep expertise in implantable technologies and global manufacturing footprint to expand closed loop offerings for movement disorders. Its collaborations with academic centers have yielded critical long-term safety and efficacy data, enhancing payer confidence. Boston Scientific, known for its robust portfolio in cardiac and peripheral interventions, has diversified into spinal cord stimulators and sacral nerve stimulators, emphasizing integrated digital platforms that support remote monitoring.

Abbott has pursued a complementary approach, repurposing legacy hardware designs into modular systems that accommodate both electrical and ultrasonic stimulation. Its acquisition of smaller innovators has accelerated pipeline development in psychiatric indications, particularly depression. LivaNova, historically focused on epilepsy and vagus nerve stimulation, has deepened its research into optogenetics and next-generation electrode materials, positioning itself at the forefront of minimally invasive therapies. Meanwhile, emerging players such as NeuroPace and Cala Health are gaining traction with novel responsive neurostimulation systems that target refractory epilepsy and essential tremor through personalized algorithms.

Across the ecosystem, strategic partnerships are reshaping competitive dynamics. Collaboration agreements between medical device manufacturers and digital health specialists are enabling seamless integration of cloud-based analytics and patient engagement tools. Joint ventures with contract research organizations facilitate expedited clinical trial execution, while alliances with insurers ensure that real-world evidence is captured to support reimbursement dossiers. This multifaceted approach underscores the importance of adaptability and cross-sector collaboration in sustaining leadership and driving continued innovation.

Empowering Industry Leaders with Actionable Recommendations to Navigate Regulatory Complexities Adoption Barriers and Accelerate Innovation in Neuromodulation

Industry leaders should prioritize the development of closed loop neuromodulation systems that harness real-time data analytics to optimize therapeutic outcomes. By investing in interoperable software architectures, organizations can ensure seamless integration into existing hospital information systems and remote patient monitoring platforms. This will enhance clinician acceptance and strengthen evidence generation for payers.

Simultaneously, companies must forge strategic alliances with research institutes and key opinion leaders to co-design clinical trials that emphasize comparative effectiveness and health economic endpoints. This collaborative model not only accelerates enrollment but also enhances the robustness of data required for reimbursement submissions. Additionally, co-development agreements with digital health providers can facilitate hybrid care models that combine device therapy with telemedicine-enabled follow-up, thereby improving patient adherence and reducing overall care costs.

To mitigate supply chain volatility induced by geopolitical factors, it is advisable to adopt a dual-sourcing strategy for critical components, balancing domestic manufacturing capabilities with selective offshore partnerships. Leaders should also explore the repurposing of existing production lines to accommodate new device formats, thereby reducing capital expenditure. Finally, adopting an agile regulatory engagement framework-leveraging accelerated approval pathways and iterative feedback loops with health authorities-will shorten time to market and reinforce compliance.

By implementing these multifaceted recommendations, stakeholders can navigate complex regulatory and commercial landscapes while maintaining a competitive edge and delivering transformative therapies to patients in need.

Detailing a Rigorous Research Methodology Encompassing Primary Interviews Secondary Data Analysis and Triangulation for Robust Market Insights

This research adopted a comprehensive methodology featuring both primary and secondary research components to ensure the validity and reliability of insights. Initially, secondary research involved an extensive review of publicly available regulatory filings, peer-reviewed journal articles, clinical trial registries, and patent databases. These sources were systematically analyzed to identify emerging technological trends, funding patterns, and evolving reimbursement frameworks across key geographies.

Following this, primary research was conducted through in-depth interviews with over 30 stakeholders, including device manufacturers, leading neurologists, biomedical engineers, and health economic specialists. These interviews provided qualitative context around strategic priorities, operational challenges, and anticipated market developments. Interview findings were then cross-referenced with secondary data to validate conclusions and identify areas of consensus or divergence.

To triangulate data, we employed a multi-dimensional framework that integrated quantitative insights derived from regulatory approvals, clinical trial outcomes, and procurement tender analyses. This approach enabled the identification of consistent patterns and outliers. Rigorous quality checks were performed throughout the research process, including peer reviews and hypothesis validation sessions. By combining these robust methods, the study offers a holistic and actionable perspective on the neuromodulation landscape.

Concluding Reflections on the Strategic Imperatives and Future Directions for Stakeholders Engaging with Emerging Neuromodulation Device Technologies

In summary, the neuromodulation device industry is at a critical juncture defined by rapid technological innovation, shifting regulatory paradigms, and evolving stakeholder expectations. Closed loop and noninvasive modalities are converging to deliver enhanced therapeutic precision, while new tariff structures and supply chain realignments are reshaping operational strategies. Companies that effectively integrate advanced analytics, foster strategic collaborations, and maintain supply chain resilience will emerge as industry frontrunners.

Looking ahead, the pursuit of personalized medicine through optogenetic and ultrasonic stimulation holds the promise of unlocking new clinical applications. However, success will depend on the ability to generate compelling real-world evidence and navigate diverse regional reimbursement frameworks. By aligning technological development with patient-centric care models and interdisciplinary partnerships, stakeholders can capitalize on the transformative potential of neuromodulation to address unmet clinical needs and drive sustainable growth.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Development of closed-loop deep brain stimulation systems for personalized neurological therapies
  • 5.2. Integration of noninvasive transcranial magnetic stimulation devices with wearable health monitors
  • 5.3. Advancements in implantable vagus nerve stimulators for treatment-resistant epilepsy and depression
  • 5.4. Emerging optogenetic neuromodulation approaches for precise wireless neural circuit control
  • 5.5. Regulatory approval pathways streamlining novel neuromodulation device clinical trials globally
  • 5.6. Adoption of AI algorithms to optimize stimulation parameters in real time for patient outcomes
  • 5.7. Rising investment in miniaturized neuromodulation systems enabling at-home patient therapy

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Neuromodulation Devices Market, by Device Type

  • 8.1. Introduction
  • 8.2. Invasive Devices
    • 8.2.1. Deep Brain Stimulators
    • 8.2.2. Sacral Nerve Stimulators
    • 8.2.3. Spinal Cord Stimulators
    • 8.2.4. Vagus Nerve Stimulators
  • 8.3. Noninvasive Devices
    • 8.3.1. Transcranial Direct Current Stimulation
    • 8.3.2. Transcranial Magnetic Stimulation

9. Neuromodulation Devices Market, by Control Mechanism

  • 9.1. Introduction
  • 9.2. Closed Loop
  • 9.3. Open Loop

10. Neuromodulation Devices Market, by Technology

  • 10.1. Introduction
  • 10.2. Electrical Stimulation
  • 10.3. Magnetic Stimulation
  • 10.4. Optogenetic Stimulation
  • 10.5. Ultrasonic Stimulation

11. Neuromodulation Devices Market, by Age Group

  • 11.1. Introduction
  • 11.2. Adult
  • 11.3. Geriatric
  • 11.4. Pediatric

12. Neuromodulation Devices Market, by Therapeutic Area

  • 12.1. Introduction
  • 12.2. Gastrointestinal & Urological Disorders
  • 12.3. Neurological Disorders
    • 12.3.1. Dystonia
    • 12.3.2. Epilepsy
    • 12.3.3. Parkinson's Disease
  • 12.4. Pain Management
    • 12.4.1. Chronic Pain
    • 12.4.2. Neuropathic Pain
  • 12.5. Psychiatric Disorders
    • 12.5.1. Depression
    • 12.5.2. Obsessive-Compulsive Disorder

13. Neuromodulation Devices Market, by End User

  • 13.1. Introduction
  • 13.2. Ambulatory Surgical Centers
  • 13.3. Clinics
  • 13.4. Hospitals
  • 13.5. Research Institutes

14. Neuromodulation Devices Market, by Distribution Channel

  • 14.1. Introduction
  • 14.2. Offline
  • 14.3. Online

15. Americas Neuromodulation Devices Market

  • 15.1. Introduction
  • 15.2. United States
  • 15.3. Canada
  • 15.4. Mexico
  • 15.5. Brazil
  • 15.6. Argentina

16. Europe, Middle East & Africa Neuromodulation Devices Market

  • 16.1. Introduction
  • 16.2. United Kingdom
  • 16.3. Germany
  • 16.4. France
  • 16.5. Russia
  • 16.6. Italy
  • 16.7. Spain
  • 16.8. United Arab Emirates
  • 16.9. Saudi Arabia
  • 16.10. South Africa
  • 16.11. Denmark
  • 16.12. Netherlands
  • 16.13. Qatar
  • 16.14. Finland
  • 16.15. Sweden
  • 16.16. Nigeria
  • 16.17. Egypt
  • 16.18. Turkey
  • 16.19. Israel
  • 16.20. Norway
  • 16.21. Poland
  • 16.22. Switzerland

17. Asia-Pacific Neuromodulation Devices Market

  • 17.1. Introduction
  • 17.2. China
  • 17.3. India
  • 17.4. Japan
  • 17.5. Australia
  • 17.6. South Korea
  • 17.7. Indonesia
  • 17.8. Thailand
  • 17.9. Philippines
  • 17.10. Malaysia
  • 17.11. Singapore
  • 17.12. Vietnam
  • 17.13. Taiwan

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Abbott Laboratories
    • 18.3.2. Aleva Neurotherapeutics SA
    • 18.3.3. Biotronik SE & Co. KG
    • 18.3.4. Boston Scientific Corporation
    • 18.3.5. BrainsWay Ltd.
    • 18.3.6. ElectroCore, Inc.
    • 18.3.7. Integer Holdings Corporation
    • 18.3.8. Laborie
    • 18.3.9. Life Science Outsourcing, Inc.
    • 18.3.10. LivaNova PLC
    • 18.3.11. Medtronic plc
    • 18.3.12. Neuromod Devices Limited
    • 18.3.13. Neuronetics, Inc.
    • 18.3.14. Neuropace Inc.
    • 18.3.15. NeuroSigma, Inc.
    • 18.3.16. Nexstim Oyj
    • 18.3.17. Saluda Medical Pty Ltd
    • 18.3.18. Soterix Medical Inc.
    • 18.3.19. Synapse Biomedical Inc.
    • 18.3.20. Synergia Medical SA
    • 18.3.21. tVNS Technologies GmbH

19. ResearchAI

20. ResearchStatistics

21. ResearchContacts

22. ResearchArticles

23. Appendix

LIST OF FIGURES

  • FIGURE 1. NEUROMODULATION DEVICES MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 18. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 22. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. ASIA-PACIFIC NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 26. ASIA-PACIFIC NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 27. NEUROMODULATION DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. NEUROMODULATION DEVICES MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 29. NEUROMODULATION DEVICES MARKET: RESEARCHAI
  • FIGURE 30. NEUROMODULATION DEVICES MARKET: RESEARCHSTATISTICS
  • FIGURE 31. NEUROMODULATION DEVICES MARKET: RESEARCHCONTACTS
  • FIGURE 32. NEUROMODULATION DEVICES MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. NEUROMODULATION DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DEEP BRAIN STIMULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DEEP BRAIN STIMULATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY SACRAL NERVE STIMULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY SACRAL NERVE STIMULATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY SPINAL CORD STIMULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY SPINAL CORD STIMULATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY VAGUS NERVE STIMULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY VAGUS NERVE STIMULATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY TRANSCRANIAL DIRECT CURRENT STIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY TRANSCRANIAL DIRECT CURRENT STIMULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY TRANSCRANIAL MAGNETIC STIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY TRANSCRANIAL MAGNETIC STIMULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CLOSED LOOP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CLOSED LOOP, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OPEN LOOP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OPEN LOOP, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ELECTRICAL STIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ELECTRICAL STIMULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY MAGNETIC STIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY MAGNETIC STIMULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OPTOGENETIC STIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OPTOGENETIC STIMULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ULTRASONIC STIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ULTRASONIC STIMULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY GASTROINTESTINAL & UROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY GASTROINTESTINAL & UROLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DYSTONIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DYSTONIA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY EPILEPSY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DEPRESSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DEPRESSION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OBSESSIVE-COMPULSIVE DISORDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OBSESSIVE-COMPULSIVE DISORDER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 105. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 107. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 109. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 111. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 113. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 115. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 117. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2025-2030 (USD MILLION)
  • TABLE 119. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 121. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 123. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 125. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 127. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 129. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 130. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 131. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 132. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 133. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 134. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 135. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 136. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 137. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 139. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 140. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 141. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 142. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 143. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 144. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2025-2030 (USD MILLION)
  • TABLE 145. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 146. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 147. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 149. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 150. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 151. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 152. UNITED STATES NEUROMODULATION DEVICES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 153. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 155. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 156. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 157. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 158. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 159. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 160. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 161. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 162. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 163. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 165. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 166. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 167. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 168. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 169. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 170. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2025-2030 (USD MILLION)
  • TABLE 171. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 172. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 173. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 175. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 176. CANADA NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 177. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 179. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 180. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 181. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 182. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 183. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 184. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 185. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 186. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 187. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 189. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 190. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 191. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 192. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 193. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 194. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2025-2030 (USD MILLION)
  • TABLE 195. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 196. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 197. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 199. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 200. MEXICO NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 201. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 203. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 204. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 205. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 206. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 207. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 208. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 209. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 210. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 211. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 213. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 214. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 215. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 216. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 217. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 218. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2025-2030 (USD MILLION)
  • TABLE 219. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 220. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 221. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 223. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. BRAZIL NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 225. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 227. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 228. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 229. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 230. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 231. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 232. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 233. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 234. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 235. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 237. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 238. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 239. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 240. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 241. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 242. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2025-2030 (USD MILLION)
  • TABLE 243. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 244. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 245. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 247. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. ARGENTINA NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2025-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 278. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 280. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 282. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 287. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 289. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 290. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 291. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY PAIN MANAGEMENT, 2025-2030 (USD MILLION)
  • TABLE 293. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 295. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 297. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. UNITED KINGDOM NEUROMODULATION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 299. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 301. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 302. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY INVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 303. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 304. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY NONINVASIVE DEVICES, 2025-2030 (USD MILLION)
  • TABLE 305. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 306. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY CONTROL MECHANISM, 2025-2030 (USD MILLION)
  • TABLE 307. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 309. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 310. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 311. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 312. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 313. GERMANY NEUROMODULATION DEVICES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)

TAB